From the Faculty of Health and Sport, University of Agder; Department of Rheumatology, Sorlandet Hospital HF, Kristiansand; Department of Rheumatology, Martina Hansens Hospital, Bærum; Department of Neuroscience, Division of Rheumatology, Norwegian University of Science and Technology, Trondheim, Norway.
K.H. Berg, PhD Student, Head of Institute of Nursing Sciences, Faculty of Health and Sport, University of Agder; G.E. Rohde, Professor, Faculty of Health and Sport, University of Agder, and Department of Rheumatology, Sorlandet Hospital HF; A. Prøven, MD, Department of Rheumatology, Martina Hansens Hospital; E.E. Benestad, Professor, Faculty of Health and Sport, University of Agder; M. Østensen, Professor Emeritus, Department of Rheumatology, Sorlandet Hospital HF; G. Haugeberg, Professor, Department of Rheumatology, Sorlandet Hospital HF, and Department of Neuroscience, Division of Rheumatology, Norwegian University of Science and Technology.
J Rheumatol. 2019 Sep;46(9):1075-1083. doi: 10.3899/jrheum.180413. Epub 2019 Feb 15.
To examine the relationship between demographics, disease-related variables, treatment, and sexual quality of life (SQOL) in men and women with axial spondyloarthritis (axSpA).
AxSpA patients were consecutively recruited from 2 rheumatology outpatient clinics in southern Norway. A broad spectrum of demographics, disease, treatment, and QOL data were systematically collected. SQOL was assessed using the SQOL-Female (SQOL-F) questionnaire (score range 18-108). Appropriate statistical tests were applied for group comparison, and the association between independent variables and SQOL-F was examined using multiple linear regression analysis.
A total of 360 (240 men, 120 women) axSpA patients with mean age 45.5 years and disease duration 13.9 years were included. Seventy-eight percent were married/cohabiting, 26.7% were current smokers, 71.0% were employed, 86.0% performed > 1-h exercise per week, and 88.0% were HLA-B27-positive. Mean (SD) values for disease measures were C-reactive protein (CRP) 8.5 (12.1) mg/l, Bath Ankylosing Spondylitis Disease Activity Index 3.1 (2.1), Bath Ankylosing Spondylitis Global Score (BAS-G) 3.8 (2.5), Bath Ankylosing Spondylitis Functional Index 2.7 (2.2), and Health Assessment Questionnaire 0.6 (0.5). The proportion of patients using nonsteroidal antiinflammatory drugs was 44.0%, synthetic disease-modifying antirheumatic drugs (DMARD) 5.0%, and biologic DMARD 24.0%. Mean (SD) total sum score for SQOL was 76.6 (11.3). In multivariate analysis, female sex, increased body mass index, measures reflecting disease activity (BAS-G and CRP), and current biologic treatment were independently associated with a lower SQOL.
Our data suggest that inflammation in patients with axSpA even in the biologic treatment era reduces SQOL.
探讨男性和女性中轴型脊柱关节炎（axSpA）患者的人口统计学、疾病相关变量、治疗与生活质量（QOL）之间的关系。
在挪威南部的 2 家风湿病门诊连续招募 axSpA 患者。系统性收集了广泛的人口统计学、疾病、治疗和 QOL 数据。采用女性生活质量问卷（SQOL-F）评估生活质量（得分范围 18-108）。采用适当的统计检验进行组间比较，采用多元线性回归分析检验自变量与 SQOL-F 的相关性。
共纳入 360 例 axSpA 患者（240 例男性，120 例女性），平均年龄 45.5 岁，病程 13.9 年。78%为已婚/同居，26.7%为当前吸烟者，71.0%有工作，86.0%每周进行>1 小时的运动，88.0%为 HLA-B27 阳性。疾病指标的平均值（标准差）为 C 反应蛋白（CRP）8.5（12.1）mg/L，Bath 强直性脊柱炎疾病活动指数（BASDAI）3.1（2.1），Bath 强直性脊柱炎全球评分（BAS-G）3.8（2.5），Bath 强直性脊柱炎功能指数（BASFI）2.7（2.2）和健康评估问卷（HAQ）0.6（0.5）。使用非甾体抗炎药的患者比例为 44.0%，合成改善病情抗风湿药（DMARD）为 5.0%，生物 DMARD 为 24.0%。SQOL 总得分的平均值（标准差）为 76.6（11.3）。多变量分析显示，女性、体重指数增加、反映疾病活动度的指标（BAS-G 和 CRP）和当前生物治疗与较低的 SQOL 独立相关。
我们的数据表明，即使在生物治疗时代，axSpA 患者的炎症也会降低生活质量。
